NASDAQ:GMAB Genmab A/S (GMAB) Stock Price, News & Analysis $28.38 +0.25 (+0.89%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$28.14▼$28.4750-Day Range$24.85▼$29.8152-Week Range$24.53▼$42.72Volume609,703 shsAverage Volume584,082 shsMarket Capitalization$18.77 billionP/E Ratio23.65Dividend YieldN/APrice Target$49.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Genmab A/S alerts: Email Address Genmab A/S MarketRank™ Stock AnalysisAnalyst RatingHold2.42 Rating ScoreUpside/Downside74.4% Upside$49.50 Price TargetShort InterestHealthy0.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.91Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth24.78%From $1.13 to $1.41 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.95 out of 5 starsMedical Sector217th out of 936 stocksPharmaceutical Preparations Industry92nd out of 436 stocks 3.2 Analyst's Opinion Consensus RatingGenmab A/S has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on 8 buy ratings, 1 hold rating, and 3 sell ratings.Amount of Analyst CoverageGenmab A/S has only been the subject of 4 research reports in the past 90 days.Read more about Genmab A/S's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.34% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genmab A/S has recently decreased by 3.48%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GMAB. Previous Next 3.3 News and Social Media Coverage News SentimentGenmab A/S has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Genmab A/S this week, compared to 4 articles on an average week.Search Interest13 people have searched for GMAB on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by InstitutionsOnly 7.07% of the stock of Genmab A/S is held by institutions.Read more about Genmab A/S's insider trading history. Previous Next 3.8 Earnings and Valuation Earnings GrowthEarnings for Genmab A/S are expected to grow by 24.78% in the coming year, from $1.13 to $1.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 23.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.26.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 23.65, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 169.33.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 1.00. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 4.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genmab A/S's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.Get our No. 1 stock (with 500%-plus upside potential) for this rare market event now. About Genmab A/S Stock (NASDAQ:GMAB)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More GMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMAB Stock News HeadlinesJuly 26 at 2:50 AM | americanbankingnews.comBrokerages Set Genmab A/S (NASDAQ:GMAB) PT at $49.50July 20, 2024 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Rating Reiterated by HC WainwrightJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 19, 2024 | markets.businessinsider.comTD Cowen Keeps Their Hold Rating on Genmab (GMAB)July 19, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Genmab A/S Increased by Analyst (NASDAQ:GMAB)July 17, 2024 | globenewswire.comGenmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024July 17, 2024 | americanbankingnews.comWilliam Blair Weighs in on Genmab A/S's Q2 2024 Earnings (NASDAQ:GMAB)June 28, 2024 | globenewswire.comEpcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular LymphomaJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 27, 2024 | globenewswire.comCompletion of Share Buy-back ProgramJune 26, 2024 | businesswire.comEPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)June 26, 2024 | globenewswire.comEPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)June 24, 2024 | investorplace.com7 Biotech Stocks to Buy on the Dip: June 2024June 24, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramJune 18, 2024 | globenewswire.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseJune 17, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramJune 12, 2024 | globenewswire.comGrant of Restricted Stock Units and Warrants to Employees in GenmabJune 11, 2024 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsSee More Headlines Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/27/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GMAB CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees2,204Year Founded1999Price Target and Rating Average Stock Price Target$49.50 High Stock Price Target$53.00 Low Stock Price Target$47.00 Potential Upside/Downside+74.4%Consensus RatingHold Rating Score (0-4)2.42 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$1.20 Trailing P/E Ratio23.65 Forward P/E Ratio25.12 P/E Growth1Net Income$631.91 million Net Margins30.74% Pretax Margin39.74% Return on Equity18.90% Return on Assets16.83% Debt Debt-to-Equity RatioN/A Current Ratio12.46 Quick Ratio12.42 Sales & Book Value Annual Sales$17.78 billion Price / Sales1.06 Cash Flow$1.26 per share Price / Cash Flow22.49 Book Value$6.95 per share Price / Book4.08Miscellaneous Outstanding Shares661,299,000Free Float651,115,000Market Cap$18.77 billion OptionableOptionable Beta0.97 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Jan G.J. van de Winkel Ph.D. (Age 63)Co-Founder, President & CEO Comp: $2.9MMr. Anthony Pagano (Age 46)Executive VP & CFO Comp: $1.03MMr. Anthony Mancini (Age 53)Executive VP & COO Comp: $1.14MMs. Birgitte Stephensen M.Sc. (Age 63)Executive VP & Chief Legal Officer Comp: $637.57kMr. Christopher Cozic (Age 45)Executive VP & Chief People Officer Comp: $782.47kDr. Martine J. van Vugt Ph.D. (Age 53)Executive VP & Chief Strategy Officer Comp: $695.53kMr. Martin Schultz (Age 48)Senior Director of Clinical Operations & Non-Independent Director Comp: $115.92kDr. Judith V. Klimovsky M.D. (Age 66)Executive VP & Chief Development Officer Comp: $1.17MDr. Tahamtan Ahmadi (Age 51)Executive VP, Chief Medical Officer & Head of Experimental Medicines Comp: $1.12MDr. Mijke Zachariasse Ph.D. (Age 50)Senior Director, Head of Antibody Research Materials & Non-Independent Director Comp: $159.39kMore ExecutivesKey CompetitorsTakeda PharmaceuticalNYSE:TAKAlnylam PharmaceuticalsNASDAQ:ALNYTeva Pharmaceutical IndustriesNYSE:TEVARoyalty PharmaNASDAQ:RPRXBioMarin PharmaceuticalNASDAQ:BMRNView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 3,283 shares on 7/26/2024Ownership: 0.011%Allspring Global Investments Holdings LLCBought 1,787 shares on 7/26/2024Ownership: 0.000%Fifth Third BancorpSold 4,330 shares on 7/22/2024Ownership: 0.007%Envestnet Portfolio Solutions Inc.Sold 1,943 shares on 7/16/2024Ownership: 0.004%Sequoia Financial Advisors LLCSold 2,417 shares on 7/16/2024Ownership: 0.003%View All Institutional Transactions Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Genmab A/S: Genmab A/S has a strong track record of developing antibody therapeutics for the treatment of cancer and other diseases, showcasing potential for future growth and innovation in the healthcare sector. Recent analyst ratings have been positive, with a consensus price target of $49.25, indicating potential for stock price appreciation. The company reported solid quarterly earnings, meeting analysts' consensus estimates and demonstrating financial stability. Genmab A/S has a market capitalization of $17.46 billion, reflecting its position as a significant player in the biopharmaceutical industry. With a beta of 0.99, Genmab A/S exhibits lower volatility compared to the market average, potentially offering a more stable investment option. Cons Investors should be bearish about investing in Genmab A/S for these reasons: Despite positive analyst ratings, the stock has experienced recent trading down trends, indicating potential short-term volatility and uncertainty in the market. The P/E ratio of 21.98 suggests that the stock may be relatively overvalued compared to industry peers, potentially limiting immediate upside potential. Genmab A/S has a fifty-two week high of $42.72, which may pose resistance levels for further stock price appreciation in the near term. The company's P/E/G ratio of 1.02 indicates that the stock may be trading at a premium relative to its earnings growth rate, potentially signaling limited room for further valuation expansion. Investors should consider the company's net margin of 30.74% and return on equity of 18.90% in evaluating the overall financial health and profitability of Genmab A/S. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, July 1, 2024. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com. GMAB Stock Analysis - Frequently Asked Questions How have GMAB shares performed this year? Genmab A/S's stock was trading at $31.84 at the start of the year. Since then, GMAB stock has decreased by 10.9% and is now trading at $28.38. View the best growth stocks for 2024 here. How were Genmab A/S's earnings last quarter? Genmab A/S (NASDAQ:GMAB) announced its earnings results on Thursday, May, 2nd. The company reported $0.16 earnings per share for the quarter, meeting analysts' consensus estimates of $0.16. The company earned $603.30 million during the quarter, compared to analysts' expectations of $594.23 million. Genmab A/S had a trailing twelve-month return on equity of 18.90% and a net margin of 30.74%. When did Genmab A/S IPO? Genmab A/S (GMAB) raised $503 million in an initial public offering on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. Who are Genmab A/S's major shareholders? Genmab A/S's top institutional shareholders include Bank of New York Mellon Corp (0.01%), Fifth Third Bancorp (0.01%), SG Americas Securities LLC (0.01%) and QRG Capital Management Inc.. How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC) and Pfizer (PFE). This page (NASDAQ:GMAB) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
